Jonathan R. Savidge
Directeur Général chez Syndesi Therapeutics SA
Profil
Jonathan R.
Savidge is currently the Chief Executive Officer at Syndesi Therapeutics SA and Kynos Therapeutics Ltd.
He is also the Non-Executive Chairman at NRG Therapeutics Ltd.
Previously, he worked as the Director of Business Development at Bicycle Therapeutics Plc and as the Senior Manager of Business Development at UCL Business Ltd.
He received his undergraduate degree from the University of Oxford and his doctorate from The University of Manchester.
Postes actifs de Jonathan R. Savidge
| Sociétés | Poste | Début |
|---|---|---|
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Directeur Général | - |
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Président | 26/04/2023 |
Kynos Therapeutics Ltd.
 Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Directeur Général | - |
Anciens postes connus de Jonathan R. Savidge
| Sociétés | Poste | Fin |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | - |
UCL Business Ltd.
 UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Jonathan R. Savidge
| University of Oxford | Undergraduate Degree |
| The University of Manchester | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
UCL Business Ltd.
UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Commercial Services |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
NRG Therapeutics Ltd.
NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
Kynos Therapeutics Ltd.
Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Health Technology |
